Subchronic oral toxicity of Rabella powder in experimental rats

Pham Thi Van Anh, Tran Thai Ha, Ta Minh Nguyet, Dinh Thi Thu Hang

Nội dung chính của bài viết

Tóm tắt

It has recently become obvious that the prevalence of obesity has been rapidly increasing in Vietnam, as well as other countries, over the past two decades. There has been a current trend for researchers to discover new natural ingredients which are safe and effective in the treatment of obesity. RABELLA powder was a herbal-derived product which contained Amorphophalus konjac (K. Koch starch). This plant was used as an oral medication for controlling body weight in the past as well as in the present. So far, the safety of this product, has not been reported yet in Vietnam. Thus, this study was designed to assess the subchronic toxicity of RABELLA powder in Wistar rats. The method used in this study followed the guidance of the World Health Organization and Organization for Economic Co-operation and Development; 2 oral doses of 1.2 g/kg b.w/day and 3.6 g/kg b.w/day was administered to rats for 12 consecutive weeks. The results show that RABELLA powder caused no significant change in the general condition, hematological indexes, functions and microscopic images of livers and kidneys. We conclude that RABELLA powder did not cause subchronic toxicity in experimental rats. Moreover, this also revealed partly the safety of RABELLA powder in clinical practice.

Chi tiết bài viết

Tài liệu tham khảo

1. World Health Organization Obesity and overweight. Geneva: WHO; 2017.
2. Ruban A, Stoenchev K, Ashrafian H, et al. Current treatments for obesity. Clin Med (Lond). 2019 May;19(3):205-212.
3. Guite NT. International Protocol and Indigenous Knowledge on Medicine and Health Care: An overview. The Asian Man. 2010;1(4):01-12.
4. World Health Organization. Global report on traditional and complementary medicine. 2019.
5. Venkatasubbu GD, Ramasamy S, Gaddam PR, et al. Acute and subchronic toxicity analysis of surface modified paclitaxel attached hydroxyapatite and titanium dioxide nanoparticles. International Journal of Nanomedicine. 2015;10:137-148.
6. De Jong WH, Carraway JW, Geertsma RE. In vivo and in vitro testing for the biological safety evaluation of biomaterials and medical devices. Biocompatibility and Performance of Medical Devices. 2012;120-158.
7. Chua M, Baldwin TC, Hocking TJ, et al. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol. 2010 Mar 24;128(2):268-78.
8. OECD. Guidelines for the testing of chemicals repeated dose oral toxicity study in rodents. Environmental Health and Safety Monograph Series on Testing and Assesment No 407. 2008.
9. World Health Organization. Guidelines for Assessing Quality of Herbal Medicines With Reference to Contaminants and Residues. Geneva; 2007.
10. Litchfield J T, Wilcoxon F A. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949;96:99-113.
11. World Health Organization. Working group on the safety and efficacy of herbal medicine. Report of regional office for the western pacific of the World Health Organization. 2000.
12. National Research Council. Toxicity testing for assessing environmental agents. Interim Report. Washington, DC, USA: National Academies Press. 2006.
13. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology. 2000;32(1):56-67.
14. Keithley JK, Swanson B, Mikolaitis SL, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908.